These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20980285)

  • 61. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Additional use of tacrolimus after switching to tocilizumab therapy in patients with primary lack of efficacy of infliximab therapy for rheumatoid arthritis.
    Mori S
    Mod Rheumatol; 2012 Nov; 22(6):947-50. PubMed ID: 22350573
    [No Abstract]   [Full Text] [Related]  

  • 63. Biologic agents for rheumatoid arthritis: 2008 and beyond.
    Sweiss NJ; Hushaw LL
    J Infus Nurs; 2009; 32(1 Suppl):S4-17; quiz S19-24. PubMed ID: 19142153
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [IL-6 targeting therapy to retard structural joint damage in patients with rheumatoid arthritis].
    Nishimoto N
    Clin Calcium; 2009 Mar; 19(3):425-31. PubMed ID: 19252253
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Development of type 1 diabetes mellitus in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor alpha.
    Richez C; Blanco P; Gin H; Schaeverbeke T
    Clin Exp Rheumatol; 2006; 24(5):607. PubMed ID: 17181936
    [No Abstract]   [Full Text] [Related]  

  • 67. [Kineret, Enbrel, Remicade and company. Recombinant drugs in rheumatoid arthritis].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2003; 32(5):376-83. PubMed ID: 14526457
    [No Abstract]   [Full Text] [Related]  

  • 68. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Wolbink GJ; de Vries N; Tak PP; Dijkmans BA; Crusius JB; van der Horst-Bruinsma IE
    Arthritis Rheum; 2009 Aug; 60(8):2541-2. PubMed ID: 19644871
    [No Abstract]   [Full Text] [Related]  

  • 69. 1,25-dihydroxy Vitamin D3 and Interleukin-6 Blockade Synergistically Regulate Rheumatoid Arthritis by Suppressing Interleukin-17 Production and Osteoclastogenesis.
    Kim H; Baek S; Hong SM; Lee J; Jung SM; Lee J; Cho M; Kwok SK; Park SH
    J Korean Med Sci; 2020 Feb; 35(6):e40. PubMed ID: 32056400
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Interlukin-6 receptor inhibitor tocilizumab: a new treatment option in rheumatoid arthritis?
    Johnson J; Wang MY
    Neurosurgery; 2008 Aug; 63(2):N8. PubMed ID: 18797345
    [No Abstract]   [Full Text] [Related]  

  • 71. [Rheumatoid polyarthritis: a new treatment].
    Perspect Infirm; 2010; 7(5):46-7. PubMed ID: 21744636
    [No Abstract]   [Full Text] [Related]  

  • 72. New therapies for treatment of rheumatoid arthritis.
    Smolen JS; Aletaha D; Koeller M; Weisman MH; Emery P
    Lancet; 2007 Dec; 370(9602):1861-74. PubMed ID: 17570481
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Tocilizumab in rheumatoid arthritis].
    Rueda Gotor J; Blanco Alonso R
    Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.
    Gibiansky L; Frey N
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):5-16. PubMed ID: 22101760
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect?
    Wendling D; Dernis E; Prati C; Frisch E; Delbosc B
    J Rheumatol; 2011 Oct; 38(10):2284. PubMed ID: 21965707
    [No Abstract]   [Full Text] [Related]  

  • 76. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New drugs for rheumatoid arthritis.
    Olsen NJ; Stein CM
    N Engl J Med; 2004 May; 350(21):2167-79. PubMed ID: 15152062
    [No Abstract]   [Full Text] [Related]  

  • 78. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).
    Yamanaka H; Tanaka Y; Inoue E; Hoshi D; Momohara S; Hanami K; Yunoue N; Saito K; Amano K; Kameda H; Takeuchi T
    Mod Rheumatol; 2011 Apr; 21(2):122-33. PubMed ID: 20953815
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
    Cronstein BN
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Adalimumab in advanced and early rheumatoid arthritis].
    Szekanecz Z
    Orv Hetil; 2009 Jul; 150(28):1333-4. PubMed ID: 19581162
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.